Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Risks factors for highly unstable response to oral anticoagulation: a case-control study.

Palareti G, Legnani C, Guazzaloca G, Lelia V, Cosmi B, Lunghi B, Marchetti G, Poli D, Pengo V; ad hoc Study Group of the Italian Federation of Anticoagulation Clinics*.

Br J Haematol. 2005 Apr;129(1):72-8.

PMID:
15801958
2.

Assessment of patient capability to self-adjust oral anticoagulant dose: a multicenter study on home use of portable prothrombin time monitor (COAGUCHECK).

Cosmi B, Palareti G, Carpanedo M, Pengo V, Biasiolo A, Rampazzo P, Morstabilini G, Testa S.

Haematologica. 2000 Aug;85(8):826-31.

3.

Genetic and environmental risk factors for oral anticoagulant overdose.

Verstuyft C, Robert A, Morin S, Loriot MA, Flahault A, Beaune P, Funck-Brentano C, Jaillon P, Becquemont L.

Eur J Clin Pharmacol. 2003 Mar;58(11):739-45. Epub 2003 Feb 18.

PMID:
12634980
4.

Acenocoumarol stabilization is delayed in CYP2C93 carriers.

Schalekamp T, van Geest-Daalderop JH, de Vries-Goldschmeding H, Conemans J, Bernsen Mj Mj, de Boer A.

Clin Pharmacol Ther. 2004 May;75(5):394-402.

PMID:
15116052
5.

[Major closed-space bleeding in patients on anticoagulation with acenocoumarol (TAO) or non-fractionned heparin(HS): a case-control study].

Martínez Lacasa J, Juan N, Juliá J, Rodríguez-Carballeira M, de Diego I, Soto R, Garau J.

An Med Interna. 2008 Jan;25(1):9-14. Spanish.

PMID:
18377188
6.

Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status.

Schalekamp T, Oosterhof M, van Meegen E, van Der Meer FJ, Conemans J, Hermans M, Meijerman I, de Boer A.

Clin Pharmacol Ther. 2004 Nov;76(5):409-17.

PMID:
15536456
7.

Determination of bleeding risk using genetic markers in patients taking phenprocoumon.

Hummers-Pradier E, Hess S, Adham IM, Papke T, Pieske B, Kochen MM.

Eur J Clin Pharmacol. 2003 Jul;59(3):213-9. Epub 2003 May 1.

PMID:
12728288
8.

[Significance of cytochrome P450 2C9 genotype for the bleeding complications in patients treated with acenocoumarol].

Márk L, Márki-Zay J, Fodor L, Kondacs A, Paragh G, Katona A.

Orv Hetil. 2005 Apr 17;146(16):739-43. Hungarian.

PMID:
15889670
9.

The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon.

Visser LE, van Vliet M, van Schaik RH, Kasbergen AA, De Smet PA, Vulto AG, Hofman A, van Duijn CM, Stricker BH.

Pharmacogenetics. 2004 Jan;14(1):27-33.

PMID:
15128048
10.

Early acenocoumarol overanticoagulation among cytochrome P450 2C9 poor metabolizers.

Verstuyft C, Morin S, Robert A, Loriot MA, Beaune P, Jaillon P, Becquemont L.

Pharmacogenetics. 2001 Nov;11(8):735-7.

PMID:
11692083
12.

The influence of patient adherence on anticoagulation control with warfarin: results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study.

Kimmel SE, Chen Z, Price M, Parker CS, Metlay JP, Christie JD, Brensinger CM, Newcomb CW, Samaha FF, Gross R.

Arch Intern Med. 2007 Feb 12;167(3):229-35.

PMID:
17296877
13.

A comparative study on the quality of oral anticoagulant therapy (warfarin versus acenocoumarol).

Pattacini C, Manotti C, Pini M, Quintavalla R, Dettori AG.

Thromb Haemost. 1994 Feb;71(2):188-91.

PMID:
8191397
14.

CYP2C9 genotypes and the quality of anticoagulation control with warfarin therapy among Brazilian patients.

Lima MV, Ribeiro GS, Mesquita ET, Victer PR, Vianna-Jorge R.

Eur J Clin Pharmacol. 2008 Jan;64(1):9-15. Epub 2007 Oct 23.

PMID:
17955230
15.

[Warfarin in the treatment of antiphospholipid syndrome].

Reshetniak TM, Kondrat'eva LV, Patrusheva NL, Patrushev LI.

Ter Arkh. 2007;79(5):47-54. Russian.

PMID:
17672075
16.

Determinants of compliance with anticoagulation: A case-control study.

Arnsten JH, Gelfand JM, Singer DE.

Am J Med. 1997 Jul;103(1):11-7.

PMID:
9236480
17.

Experience with INR self-management: patient selection and complication rates.

Voeller H, Dovifat C, Wegscheider K.

Z Kardiol. 2005 Dec;94(12):801-7.

PMID:
16382380
18.

Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants.

Visser LE, van Schaik RH, van Vliet M, Trienekens PH, De Smet PA, Vulto AG, Hofman A, van Duijn CM, Stricker BH.

Clin Pharmacol Ther. 2005 Jun;77(6):479-85.

PMID:
15961979
19.

Cytochrome P450 2C9 polymorphism and acenocoumarol therapy.

Mark L, Marki-Zay J, Fodor L, Hajdara I, Paragh G, Katona A.

Kardiol Pol. 2006 Apr;64(4):397-402; discussion 403-4. English, Polish.

20.

[Knowledge of patients undergoing long-term acenocumarol treatment about the safety of anticoagulant therapy].

Sawicka-Powierza J, Ołtarzewska AM, Chlabicz S.

Pol Merkur Lekarski. 2007 Jan;22(127):36-40. Polish.

PMID:
17477088

Supplemental Content

Support Center